Adam M. Veness, SVP, General Counsel and Secretary at Dianthus Therapeutics, Inc. /DE/ (DNTH), sold 30,000 shares at $80.34 ($2.4M) on 2026-06-17, disclosed to the SEC on 2026-06-18.
Scheduled sale ($2.4M) by SVP, General Counsel and Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $80.34 | 16,771 | $1.3M | 55.6% |
| 2 | $81.38 | 13,229 | $1.1M | 44.4% |
| Total | $80.80 avg | 30,000 | $2.4M | 100% |
| Filing → |
| XLRN | SELL | 2021-09-09 | $184K | — | Filing → |
| XLRN | SELL | 2021-01-06 | $252K | — | Filing → |
| XLRN | SELL | 2020-09-09 | $358K | — | Filing → |